During the past decade, Azienda Ospedaliera S. Andrea - Università La Sapienza conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 8 clinical trials were completed, i.e. on average, 53.3% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 8 clinical trials were completed. i.e. 114.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Ospedaliera S. Andrea - Università La Sapienza" #1 sponsor was "Celgene" with 5 trials, followed by "Hoffmann-La Roche" with 3 trials sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored, "Ferring Pharmaceuticals" with 2 trials sponsored and "Amgen" with 2 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliera S. Andrea - Università La Sapienza" #1 collaborator was "Chugai Pharmaceutical" with 1 trials as a collaborator, "Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation" with 1 trials as a collaborator and "Novartis" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliera S. Andrea - Università La Sapienza" are "Multiple Sclerosis" (3 trials), "Leukemia, Myeloid, Acute" (2 trials), "Prostate Cancer" (2 trials), "Schizophrenia" (2 trials) and "Depressive Disorder, Treatment-Resistant" (1 trials). Many other conditions were trialed in "Azienda Ospedaliera S. Andrea - Università La Sapienza" in a lesser frequency.

Most popular intervention types in "Azienda Ospedaliera S. Andrea - Università La Sapienza" are "Drug" (18 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Degarelix" (2 trials), "AG-120" (1 trials), "AG-221" (1 trials) and "AMG334" (1 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Ospedaliera S. Andrea - Università La Sapienza" are 17 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Azienda Ospedaliera S. Andrea - Università La Sapienza". undefined are not yet recruiting, 4 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Azienda Ospedaliera S. Andrea - Università La Sapienza, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Ospedaliera S. Andrea - Università La Sapienza, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".